Foundation for Neglected Disease Research

Positive results from Phase 2A clinical trial of TBA-7371, a new drug candidate for tuberculosis Foundation for Neglected Disease Research is proud to announce that its partners, Bill & Melinda Gates Medical Research Institute and TB Alliance, have successfully completed the Phase 2A Early Bactericidal Activity clinical trial of TBA-7371, a novel DprE1 inhibitor for the treatment of tuberculosis. The results were presented at the 2023 International Union Against Tuberculosis and Lung Disease (The Union) World Conference on Lung Health in Paris. TBA-7371 was well tolerated and showed significant dose-dependent bactericidal activity with 14 days of treatment in patients with drug-susceptible pulmonary tuberculosis. TBA-7371 could have significant potential in the treatment of TB.

World TB Day Dear friend,   On this World TB Day, we would like to thank you for being a part of Foundation for Neglected Disease Research (FNDR’s) journey so far.   Tuberculosis remains one of the world’s deadliest diseases with catastrophic socio-economic costs. Every year, it affects more than 10 million people and causes nearly one-and-a-half million deaths, mostly in developing countries. The rise in drug resistance is making tuberculosis treatments harder and longer, often with poorer outcomes for patients. FNDR is committed to discovering and developing new drugs to overcome this obstacle in the treatment of tuberculosis. FNDR’s lead drug candidate for tuberculosis treatment, TBA-7371, has successfully completed Phase 2A clinical trials with positive results and is being further explored for Phase 2b development in TB patients.   With your support, FNDR continues to make strides in discovering and developing new drugs for tuberculosis and other infectious diseases that have a high socio-economic impact, such as COVID-19, Influenza, RSV, rabies, bacterial infections, fungal infections, malaria, and leishmania. To help us continue the long fight against tuberculosis and neglected diseases, please donate to FNDR here: https://www.fndr.in/donate. Please note that donations are eligible for tax exemption (50%) under Section 80G. Your contribution matters!   Best wishes, Shridhar Narayanan, Ph.D. Chairman and CEO Foundation for Neglected Disease Research (FNDR)

Thanks to ISCR for the opportunity to present about the FNDR journey...was a wonderful exchange of ideas

Delighted to be part of the editorial team on these important topics